SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                   FORM 10-QSB


 [x]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         EXCHANGE ACT OF 1934.

                 For the quarterly period ended January 31, 1997

                                       OR

 [ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
         ACT OF 1934.

         For the transition period from                to
                                        --------------    ----------------


                         Commission file number 2-86360



                                INFORMEDICS, INC.
        (Exact name of small business issuer as specified in its charter)

       Oregon                                              93-0750571
-------------------------------------------------------------------------------
(State of incorporation)                              (I.R.S. Employer
                                                       Identification No.)



                              4000 Kruse Way Place
                                Bldg 3, Suite 300
                            Lake Oswego, Oregon 97035
                     --------------------------------------
                    (Address of principal executive offices)

                    Issuer's telephone number: (503) 697-3000

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the issuer was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.     Yes /X/   No / /

Number of shares of Informedics, Inc. $.01 par value common stock outstanding as
of February 28, 1997: 2,650,307.



<PAGE>




                                INFORMEDICS, INC.


                         Part I - Financial Information




The information included herein is unaudited. However, such information reflects
all adjustments (consisting solely of normal, recurring adjustments) which are,
in the opinion of management, necessary for a fair presentation of the results
of operations for the interim periods. The interim financial information and
notes thereto should be read in conjunction with the Company's latest annual
report on Form 10-KSB. The results of operations for the three months ended
January 31, 1997 are not necessarily indicative of results to be expected for
the entire year.


<PAGE>


INFORMEDICS,  INC.
STATEMENTS OF OPERATIONS

                                             Three Months Ended January 31,
                                        ---------------------------------------
                                              1997                  1996
                                        ---------------        ----------------

REVENUE:
Product Sales                             $  149,761             $  426,880
Customer Service and Support                 695,935                857,301
                                          ----------             ----------

Total Revenue                                845,696              1,284,181
                                          ----------             ----------

COSTS AND EXPENSES:
Cost of Products Sold                         28,211                233,825
Cost of Customer Service and Support         501,086                720,790
Selling & Administrative Expenses            485,147                628,061
Depreciation & Amortization                  101,610                 87,198
                                          ----------             ----------

Total Costs and Expenses                   1,116,054              1,669,874
                                          ----------             ----------

Operating Loss                              (270,358)              (385,693)
                                          ----------             ----------

OTHER INCOME (EXPENSE):
Interest Expense                              (3,835)                    (7)
Interest Income                                8,680                  4,104
Other Income                                   3,669                   (214)
                                          ----------             ----------

Total Other Income                             8,514                  3,883
                                          ----------             ----------

LOSS BEFORE INCOME TAXES                    (261,844)              (381,810)

INCOME TAX BENEFIT                                 -               (145,963)
                                          ----------             ----------

NET LOSS                                  $ (261,844)            $ (235,847)
                                          ==========             ==========

Weighted Average Number of Common
  Shares Outstanding and Common Stock
  Equivalents Outstanding                  2,650,307              2,643,404
                                          ==========             ==========




LOSS PER SHARE                            $    (0.10)            $    (0.09)
                                          ==========             ==========


See Note to Financial Statements.


<PAGE>


INFORMEDICS, INC.
BALANCE SHEETS

ASSETS

                                        January 31, 1997       October 31, 1996
                                        ----------------       ----------------


CURRENT ASSETS:

Cash                                      $  370,220             $  323,217
Accounts Receivable, less allowance
   for doubtful accounts of $  31,462 in
   1997 and $ 28,439 in 1996                 581,882                681,303
Inventories                                   18,426                 23,833
Prepaid Expenses and Other Current Assets     38,702                 36,150
Deferred Income Taxes                        165,282                182,483
Current Portion of Long-Term                  11,928                 11,928
Receivable
Current Portion of Notes Receivable           60,161                 54,095
                                          ----------             ----------

Total Current Assets                       1,246,601              1,313,009
                                          ----------             ----------


FIXED ASSETS:

Furniture and Fixtures                       134,282                134,282
Machinery and Equipment                      583,447                583,961
Automobiles                                   29,138                 29,138
Leasehold Improvements                        24,100                 20,442
Other Fixed Assets                           136,805                136,805
                                          ----------             ----------
                                             907,772                904,628
Less accumulated depreciation
  and amortization                           707,860                672,300
                                          ----------             ----------

Total Fixed Assets                           199,912                232,328
                                          ----------             ----------


OTHER ASSETS:

Long-Term Account Receivable                  39,760                 42,742
Notes Receivable                             289,537                305,415
Software Development Costs,
   less accumulated  amortization
   of $603,404 in 1997 and 
   $542,884 in 1996                          270,053                305,102
Covenants Not to Compete,
   less accumulated amortization
   of $483,556 in 1997
   and $479,698 in 1996                       10,489                 14,348
Deferred Income Taxes, less valuation
   reserve of $98,393 in 1997                630,261                613,060
Other                                         39,299                 41,816
                                          ----------             ----------

Total Other Assets                         1,279,399              1,322,483
                                          ----------             ----------

TOTAL ASSETS                              $2,725,912             $2,867,820
                                          ==========             ==========

See Note to Financial Statements


<PAGE>


INFORMEDICS, INC.
BALANCE SHEETS

LIABILITIES AND STOCKHOLDERS' EQUITY


                                        January 31, 1997       October 31, 1996
                                        ----------------       ----------------


CURRENT LIABILITIES:

Accounts Payable and Accrued Expenses:
  Trade Accounts                          $   99,156             $  115,543
  Customer Deposits                           11,255                  4,120
  Accrued Wages, Payroll Taxes and
    Employee Benefits                        137,045                175,285
  Other Accrued Liabilities                    7,925                    767
Revolving Line of Credit                           -                125,000
Deferred Revenue                           1,566,782              1,274,687
Current Portion of Deferred Rent              13,033                 13,033
Current Portion of Deferred Gain
  on Sale of Assets                           21,398                 19,615
                                          ----------             ----------

Total Current Liabilities                  1,856,594              1,728,050

LONG-TERM OBLIGATIONS:

Deferred Rent                                 27,153                 30,411
Deferred Gain on Sale of Assets               82,025                 87,375
                                          ----------             ----------

Total Current Liabilities and
  Long-Term Obligations                    1,965,772              1,845,836
                                          ----------             ----------


STOCKHOLDERS' EQUITY:

Preferred Stock, $ .01 par value:
  authorized 5,000,000 shares;
  no shares outstanding                            -                      -
Common Stock, $.01 par value:
  authorized 15,000,000 shares;
  shares outstanding:  2,650,307
  in 1997 and 1996                            26,503                 26,503
Capital in Excess of Par Value             1,914,213              1,914,213
Note Receivable from Stockholder             (22,000)               (22,000)
Accumulated Deficit                       (1,158,576)              (896,732)
                                          ----------             ----------

Total Stockholders' Equity                   760,140              1,021,984
                                          ----------             ----------


TOTAL LIABILITIES AND STOCKHOLDERS'
EQUITY                                    $2,725,912             $2,867,820
                                          ==========             ==========


See Note to Financial Statements.





<PAGE>


INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS

                                             Three Months Ended January 31,
                                        ---------------------------------------
                                              1997                  1996
                                        ---------------        ----------------


CASH FLOWS FROM OPERATING ACTIVITIES:

  Net loss                                $  (261,844)           $  (235,847)

ADJUSTMENTS TO RECONCILE NET
LOSS TO NET CASH PROVIDED
BY OPERATING ACTIVITIES:
 Depreciation and Amortization                101,610                 87,198
 Provision for losses on accounts
   receivable                                   3,023                 28,000
 Deferred Income Taxes                              -               (146,623)
Tax benefits from stock options exercised           -                    650
 Gain on sale of assets                        (3,567)                     -
 Changes in Assets and Liabilities:
   Accounts Receivable                         99,380                (97,257)
   Income taxes receivable                          -                 29,087
   Inventories                                  5,407                     36
   Prepaid Expenses and Other Current Assets   (2,552)                27,432
   Accounts Payable and Accrued Expenses      (40,334)                30,905
   Notes Receivable                             9,499
   Deferred Revenue                           292,095                484,235
   Deferred Rent                               (3,258)                (3,258)
                                          -----------            -----------
Net cash provided by operating activities     199,459                204,558
                                          -----------            -----------

INVESTING ACTIVITIES:
 Property additions                            (4,815)               (55,609)
 Capitalized software development costs       (25,158)              (110,566)
 Other                                          2,517                  3,436
                                          -----------            -----------
 Net cash used for investing activities       (27,456)              (162,739)
                                          -----------            -----------


FINANCING ACTIVITIES:
 Decrease in revolving line of credit        (125,000)                     -
 Proceeds from issuance of common stock             -                  2,545
                                          -----------            -----------
 Net cash provided by (used for)
   financing activities                      (125,000)                 2,545
                                          -----------            -----------

NET INCREASE IN CASH                           47,003                 44,364

CASH AT BEGINNING OF QUARTER                  323,217                534,260
                                          -----------            -----------

CASH AT END OF QUARTER                    $   370,220            $   578,624
                                          ===========            ===========



<PAGE>


INFORMEDICS, INC.
STATEMENTS OF CASH FLOWS

                                             Three Months Ended January 31,
                                        ---------------------------------------
                                              1997                  1996
                                        ---------------        ----------------

Supplemental Disclosures of Cash Flow
 Information:

Cash paid for:
 Interest                                 $   3,835              $      7

 Income Taxes Received                            -               (29,077)




See Note to Financial Statements.



<PAGE>


INFORMEDICS, INC.
NOTE TO FINANCIAL STATEMENTS


1.   SIGNIFICANT ACCOUNTING POLICIES

     Industry Segment
     ----------------

     The Company derives its revenue solely from the sales and servicing of
     microcomputer software and related hardware.

     Inventories
     -----------

     Inventories are stated at the lower of cost or market. Specific
     identification is used to determine the costs of hardware and software
     inventory.

     Fixed Assets
     ------------

     Fixed Assets are stated at cost, less accumulated depreciation and
     amortization. The costs of fixed assets are depreciated over the estimated
     useful lives (two to five years) of the assets using the straight-line
     method. Leasehold improvements are amortized over the term of the lease
     (five years).

     Customer Service and Support Revenue
     ------------------------------------

     Customer service and support revenue represents revenue earned from
     hardware and software maintenance contracts, training, installation of new
     systems, and general software support and programming services provided to
     customers. Under renewable maintenance contracts, the Company provides, for
     a term of generally not more than one year, essentially all maintenance and
     repairs resulting from the normal and intended use of its products.
     Deferred revenue on maintenance contracts is amortized by the straight-line
     method over the life of the contracts.

     Revenue Recognition
     -------------------

     Revenue from sales of software and hardware is generally recorded when the
     product is shipped. Revenue from custom software products, which are
     marketed to customers primarily under perpetual license arrangements, is
     recorded at the time the product is installed and accepted by the customer.
     Revenue from services other than maintenance contracts is recognized as
     performed.

     Income Taxes
     ------------

     Income taxes are accounted for using the methodology established by
     Statement of Financial Accounting Standards (SFAS) No.109, "Accounting for
     Income Taxes", which requires an asset and a liability approach to
     financial accounting and reporting for income taxes. Deferred income tax
     assets and liabilities are computed for differences between the financial
     statement and tax bases of assets and liabilities that will result in
     taxable or deductible amounts in the future. A valuation allowance is
     established when necessary to reduce deferred tax assets to amounts
     expected to be realized based on enacted tax laws and rates applicable to
     the periods in which the differences are expected to affect taxable income.
     Income tax expense is the tax payable or refundable for the period, plus or
     minus the change during the period in deferred tax assets and liabilities.



<PAGE>


INFORMEDICS, INC.
NOTE TO FINANCIAL STATEMENTS


     Software Development Costs
     --------------------------

     Certain software development costs are being capitalized and amortized over
     the estimated economic life of the software, on a straight-line method,
     commencing when each product or enhancement is available for general
     release. Amortization using the straight-line method for the three-month
     periods ended January 31, 1997 and 1996 was $60,520 and $20,173,
     respectively.

     Covenants Not to Compete
     ------------------------

     Covenants not to compete are stated at the estimated value of the
     consideration given for the covenants (including the present value of any
     future payments to be made under each agreement), less accumulated
     amortization. The costs of the covenants are being amortized over four or
     seven years, using the straight-line method. Amortization for the
     three-month periods ended January 31, 1997 and 1996 was $3,859 and $19,291,
     respectively.

     Loss Per Share
     --------------

     Loss per share is computed on the basis of weighted average number of
     shares outstanding plus common stock equivalents which would arise from the
     exercise of stock options and warrants. Common stock equivalents are
     excluded from the calculation of net loss per share for the three months
     ended January 31, 1997 and 1996, as they are antidilutive.

     Cash and Cash Equivalents
     -------------------------

     The Company considers cash on hand, deposits in bank and highly liquid debt
     instruments purchased with original maturity dates of three months or less,
     as cash.

     Accounting Changes
     ------------------

     In October 1995, the Financial Accounting Standards Board issued Statement
     of Financial Accounting Standards (SFAS) No. 123, "Accounting for
     Stock-Based Compensation". This statement establishes an alternative method
     of accounting that requires recognizing as expense the fair value of
     employee stock options and other stock-based awards at the grant date. SFAS
     No. 123 also allows the continuation of the current accounting treatment
     under which the Company does not recognize compensation expense for the
     stock options it awards to employees. Since the Company is electing to
     retain its current method, it will be required to present pro forma
     disclosures in its 1997 annual financial statements as if the fair value
     based method had been applied.

     Reclassifications
     -----------------

     Certain prior year amounts have been reclassified to conform to the current
     year presentation. These reclassifications have no effect on net income.


<PAGE>


INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

THE FOLLOWING DISCUSSION INCLUDES CERTAIN FORWARD-LOOKING STATEMENTS. THOSE
STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES, WHICH COULD CAUSE ACTUAL
RESULTS TO DIFFER MATERIALLY FROM THE EXPECTATION STATED, INCLUDING THE
FOLLOWING: SLOWER THAN EXPECTED SALES OF INFORMEDICS' PRODUCTS, DETERIORATION OF
BUSINESS CONDITIONS GENERALLY OR SPECIFICALLY IN THE HEALTH-CARE INDUSTRY,
REGULATORY CHANGES INVOLVING HEALTH CARE, COMPETITIVE FACTORS AND PRICE
PRESSURES.

Highlights

On October 31, 1996, the Company sold certain assets of its ClinicManager
product line. As expected, the sale resulted in improved operating results as
the Company reduced its operating loss from $385,693 in the first quarter of
1996 to $270,358 in the first quarter of 1997.

The elimination of the ClinicManager product line from the Company's revenue
base resulted in a decrease in product sales and in customer service and support
revenue. Total revenue decreased from $1,284,181 for the first quarter of 1996
to $845,696 for the first quarter of 1997.

During the first quarter of 1997, the Company continued to invest a large
portion of its revenue in the development of its software products. In the first
quarter of 1997, the Company spent $282,875 or 33% of revenue for the
development of new software, the enhancement and maintenance of existing
software, and improvements to the Company's software development processes to
comply with FDA regulations. In the first quarter of 1996, the Company spent
$388,338 or 30% of revenue for similar development activities. Of the total
costs incurred, the Company capitalized $25,158 in first quarter 1997, compared
to $110,566 in first quarter 1996.

During the first quarter of 1997, the Company paid off its revolving line of
credit, which had a balance of $125,000 at October 31, 1996. In addition, the
Company's cash position increased from $323,217 at October 31, 1996 to $370,220
at January 31, 1997.

During the first quarter of 1997, the Company established a valuation reserve of
$98,393 for its deferred income tax assets, which offset the income tax benefit
for the quarter. As a result, the net loss for first quarter 1997 was higher
than the net loss for first quarter 1996.

On February 12, 1997, the National Association of Securities Dealers (NASD)
moved the trading of the Company's stock from the Nasdaq SmallCap Market to the
NASD Bulletin Board. The move initiated by Nasdaq resulted from the Company's
inability to meet the Nasdaq listing standard of a minimum bid price of $1.00
per share. All of the Company's current market makers trade securities through
the NASD Bulletin Board and management anticipates that these market makers will
continue to trade the Company's stock.

Results of Operations - Material Changes

The decrease of $277,119 in product sales for first quarter 1997 as compared to
first quarter 1996 resulted from the loss of revenue from the ClinicManager
product line and a decrease in the number of laboratory systems sold. The
decrease in the number of laboratory systems sold in first quarter 1997 resulted
from a turnover in the Company's sales staff. During the second quarter of 1997,
the Company expects to hire additional salespersons in order to increase product
sales in future periods. Management believes that product sales for 1997 will
continue to lag 1996 results until the new sales of its IntraMed.net product
line exceed previous ClinicManager sales levels.



<PAGE>


INFORMEDICS, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS

The decrease in customer service and support revenue of $161,366 for first
quarter 1997 as compared to first quarter 1996 resulted from the loss of revenue
from the ClinicManager product line of $104,764 and from a decrease in the
number of customers who purchased the Company's hardware support services. The
decrease in the number of customers who purchased the Company's hardware support
services resulted from customers purchasing hardware with extended on-site
warranties and from customers who elect to service the hardware with in-house
personnel or local hardware support vendors.

The decrease of $205,614 in the cost of products sold in first quarter 1997 as
compared to first quarter 1996 resulted from a decrease in hardware sales of
$242,968. The decrease in hardware sales resulted from a loss of revenue from
the ClinicManager product line, a decrease in the number of laboratory systems
sold and a decrease in hardware sales related to the Company's lab order entry
product line as Quest Diagnostics, Inc. elected to purchase its hardware from
another vendor.

The decrease of $219,704 or 30% in cost of customer service and support resulted
from a reduction in staff and other costs as a result of the sale of the
ClinicManager product line. Management anticipates that cost of customer service
and support for the remainder of 1997 will be less than comparable periods in
1996.

The decrease of $142,914 or 23% in selling and administration expense in first
quarter 1997 resulted from a reduction in staff and other costs as a result of
the sale of the ClinicManager product line. In addition, a turnover in the
Company's sales staff resulted in fewer salespersons on staff in first quarter
1997 when compared to first quarter 1996. The reduction in sales staff in 1997
resulted in lower wages and benefits for first quarter 1997 when compared to
first quarter 1996. Although selling and administration expenses were less in
first quarter 1997 than in first quarter 1996, management anticipates that these
expenses will increase during the remainder of 1997 as the Company plans to
expand its sales and marketing efforts of its IntraMed.net and LifeLine product
lines.

Liquidity - Capital Resources

The Company's cash position grew from $323,217 on October 31, 1996 to $370,220
on January 31, 1997. The net cash provided by operating activities during first
quarter 1997 of $199,459 was sufficient to cover the net cash used to acquire
additional assets, fund the development of the Company's software and pay off
the revolving line of credit. Based upon the anticipation of higher product
sales and reduced operating expenses, management believes that the Company's
current cash position and available funds under its revolving line of credit
agreement will be sufficient to fund its operating and investment activities for
the remainder of fiscal 1997.

Continuing losses and an increase in the deferred revenue liability on January
31, 1997, when compared to October 31, 1996, resulted in a negative working
capital of $609,993 on January 31, 1997 as compared to a negative working
capital of $415,041 on October 31, 1996. Excluding the deferred revenue
liability, which is a liability for future services, the Company's working
capital on January 31, 1997 was $956,789, compared to $859,646 on October 31,
1996.

Capital expenditures for property additions were $4,815 in first quarter 1997
compared to $55,609 in first quarter 1996. The decrease resulted from
management's decision to reduce capital expenditures in 1997. Management
anticipates that capital expenditures for property additions for the remainder
of 1997 will continue to be less than 1996 amounts.

The Company has a $700,000 uncommitted revolving line of credit with the
Company's bank. At January 31, 1997, the Company had paid off the balance of the
revolving line of credit. All of the assets of the Company are pledged as
security for the line of credit. Terms of the revolving line of credit require
the Company to maintain certain financial ratios. As of the date of this
Quarterly Report, the Company has maintained the required ratios. The Company is
in the process of renewing the line of credit, which expires April 15, 1997.
Management anticipates that the line of credit will be renewed under the same
terms and conditions.


<PAGE>


                                INFORMEDICS, INC.

                           Part II - Other Information



Item 6.   Exhibits and Reports on Form 8-K

          (a)  Exhibits.

               10(a)*    Employment Agreement between the Company and Gerald P.
                         Kelly, dated August 9, 1996.

               27        Financial Data Schedule

          (b)  Reports on Form 8-K. On November 15,1996, the Company filed Form
               8-K, dated October 31, 1996. In the Form 8-K, the Company
               reported that it sold certain assets of its ClinicManager product
               line to Adaptive Health Systems of Washington, Inc.


-----------------------------
         *  Management contract or compensatory plan or arrangement.


<PAGE>



                                   SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.



                                              INFORMEDICS, INC.
                                              (Registrant)


Date:     March 13, 1997                      By: /s/ John Tortorici
                                                 -------------------
                                                 John Tortorici,
                                                 Chairman and Chief
                                                 Executive Officer



Date:     March 13, 1997                      By: /s/ Dale E. Conner
                                                 -------------------
                                                 Dale E. Conner,
                                                 Vice President and
                                                 Chief Financial Officer







<PAGE>


                                   FORM 10-QSB

                                  Exhibit Index

Exhibit
-------

10(a)          Employment Agreement between the Company and
               Gerald P. Kelly, dated August 9, 1996.

27             Financial Data Schedule